The content on this site is intended for healthcare professionals only
Dr Elena Zamagni speaks to ecancer about a talk she presented at EMN 2024 on treatment options for late-stage relapsed/refractory multiple myeloma (RRMM). Namely CAR-T, bispecifics or antibody-drug conjugates (ADCs).
She explains that, while these different treatment options are agreed on, the criteria of choice needs to be discussed.
Dr Zamagni details that CAR-T is generally agreed to be for subsets of patients, bispecifics for almost all patients (apart from the elderly and frail) and ADCs for elderly and frail patients.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
EHA 2024: Multiple myeloma roundup
Immune therapy with belantamab mafodotin and elotuzumab shows encouraging safety profile and preliminary efficacy in RRMM
Ciltacabtagene autoleucel benefit for lenalidomide-refractory FHR multiple myeloma
Multiple myeloma in a resource constrained setting
Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma
